Verastem, Inc. (VSTM)
Nasdaq: VSTM · Pharmaceutical Preparations · Needham, MA · filing with the SEC since 2011
Who owns Verastem, Inc.
As filed with the SECHolders of 5% or more
7
Deep Track Capital, LP holds 9.99% of Common stock, $0.0001 par value per share, as its SCHEDULE 13G filed Nov 21, 2025 says.
Directors and officers
12
report now, of 29 people on the record since 2012. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Deep Track Capital, LP
SCHEDULE 13G · filed Nov 21, 2025 · Common stock, $0.0001 par value per share
RTW Investments, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value · 9.9% in Feb 17, 2026
Armistice Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common stock, $0.0001 par value per share · 5.23% in May 15, 2026
Soleus Capital Management, L.P.
SCHEDULE 13G/A · filed Feb 11, 2025 · Common Stock
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 30, 2026 · Common Stock · 6% in Oct 17, 2025
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Polar Capital Holdings Plc
SCHEDULE 13G/A · filed Jul 8, 2026 · Common stock, $0.0001 par value per share · reported falling below 5%, from 5.09% in Jan 5, 2026
Logos Global Management LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock · reported falling below 5%, from 6.2% in Jul 28, 2025
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 7.13% in Nov 14, 2025
Stonepine Capital Management, LLC
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock · reported falling below 5%, from 5% in Aug 6, 2025
Bvf Partners L P/il
SCHEDULE 13G/A · filed Aug 13, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 9.99% in Aug 13, 2025
Foresite Capital Fund VI LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · reported falling below 5%, from 5.1% in Oct 23, 2025
Orin Hirschman
SCHEDULE 13G/A · filed Jul 29, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6.1% in Jan 21, 2025
Orbimed Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.6% in May 15, 2025
Alyeska Investment Group, L.P.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Soleus Capital Management, L.P.
SCHEDULE 13G/A · filed May 2, 2025 · Common Stock · reported falling below 5%
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.18% in Feb 17, 2026
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.1% in Jul 28, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 6.23% in Jul 29, 2025
Barclays PLC
SCHEDULE 13G/A · filed Aug 12, 2025 · COMMON-STOCK · reported falling below 5%, from 8.87% in Mar 21, 2025
What VSTM reports owning in othersstakes of 5% or more, and other ties
Verastem, Inc. reports no stake in another company in the record.
Insider tradesForm 4
32sales
0purchases
32sales on a scheduled plan
6people selling
$1.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 5, 2025 to Nov 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 46 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO | 22 | $800,000 | 22 | 0 | $0 |
| Kauffman Michael | President of Development | 1 | $100,000 | 1 | 0 | $0 |
| Calkins Daniel | Chief Financial Officer | 6 | $100,000 | 6 | 0 | $0 |
| Bunn Paul A. | director | 1 | $100,000 | 1 | 0 | $0 |
| Stuglik Brian M | Chief Executive Officer | 1 | $0 | 1 | 0 | $0 |
| Gagnon Robert E. | Chief Financial Officer | 1 | $0 | 1 | 0 | $0 |